What is ARKO Labs?
ARKO Laboratories is a seasoned player in the biologics industry, specializing in the development and manufacturing of vaccines for the swine and poultry sectors. With over four decades of experience, the company has established a reputation for delivering high-quality, competitively priced products. ARKO's portfolio includes a diverse range of vaccines designed for swine, turkeys, and pigeons, with a consistent emphasis on ease of administration and food safety. The company is noted for its pioneering work in the biologics field, having developed the first federally licensed vaccines for several diseases. ARKO Labs also provides essential technical assistance and consultation, supported by a team of experienced veterinarians, reinforcing its commitment to client success and industry advancement.
How much funding has ARKO Labs raised?
ARKO Labs has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for ARKO Labs?
The recent major strategic investment positions ARKO Labs for significant expansion and innovation within the animal health market. As a company operating within the large-scale late-stage funding environment, ARKO is likely to leverage this capital to enhance its research and development capabilities, potentially broadening its vaccine pipeline or exploring new disease targets. Further investment may also be directed towards scaling manufacturing operations to meet growing demand, expanding its market reach both domestically and internationally, and strengthening its distribution networks. The strategic nature of this financing suggests potential collaborations or partnerships that could accelerate product development and market penetration, solidifying ARKO's competitive edge in vaccine solutions for the swine and poultry industries.
See full ARKO Labs company page
